Karyopharm Therapeutics (KPTI) EBT (2012 - 2026)

Karyopharm Therapeutics (KPTI) has reported EBT for 15 consecutive years, with -$67.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 80.11% year-over-year to -$67.0 million; the trailing twelve-month figure through Jun 2026 stood at -$239.6 million (down 93.77% YoY), and the FY2025 full-year result was -$196.0 million, down 156.39% from the prior year.
• EBT climbed to -$67.0 million in Q2 2026 per KPTI's latest filing, from -$102.3 million in the prior quarter.
• Across five years, EBT topped out at $23.9 million in Q2 2024 and bottomed at -$102.3 million in Q4 2025.
• Historically, EBT has averaged -$38.1 million across 5 years, with a median of -$36.3 million in 2022.
• The sharpest annual moves came in 2024 and 2025: EBT surged 173.41% in 2024, then plunged 255.97% in 2025.
• Over 5 years, EBT stood at -$39.3 million in 2022, then slipped by 6.69% to -$42.0 million in 2023, then climbed by 26.18% to -$31.0 million in 2024, then slumped by 230.22% to -$102.3 million in 2025, then soared by 34.46% to -$67.0 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$67.0 million, -$102.3 million, and -$33.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.